The Course of Adverse Events in Venlafaxine XR Treatment in Generalized Anxiety Disorder

被引:3
|
作者
Rickels, Karl [1 ]
Gallop, Robert [2 ]
Cleary, Sean [3 ]
机构
[1] Univ Penn, Dept Psychiat, 3535 Market St,Suite 670, Philadelphia, PA 19146 USA
[2] West Chester Univ, Dept Math, Appl Stat Program, W Chester, PA USA
[3] Harcum Coll, Dept Gen Studies, Media, PA USA
关键词
adverse events; generalized anxiety disorder; attrition; TOLERABILITY;
D O I
10.1097/JCP.0000000000001027
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose The time course of adverse events is an important factor for patient management. Clinicians are better able to prepare patients for specific adverse events, which leads to better treatment adherence. Methods Adverse events were followed longitudinally for 6 months during the open-label phase of a relapse prevention trial with 264 patients with generalized anxiety disorder. Adverse events were assessed at each treatment visit using a 21-item checklist. Logistic regression modeling, continuation ratio modeling, and hierarchical linear modeling were used to determine whether adverse events led to early attrition and whether adverse events decreased in enrolled patients over time. Findings Adverse events were found to have decreased highly significantly during treatment. A highly significant race effect was found in that whites had a significantly higher adverse event rate than did nonwhites. Early attrition rates were predicted by presence of nausea and fatigue, late attrition by dizziness, nervousness, and sexual dysfunction.
引用
收藏
页码:258 / 260
页数:3
相关论文
共 50 条
  • [41] Escitalopram versus venlafaxine XR in the treatment of major depressive disorder
    Montgomery, S.
    Andersen, H.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S233 - S233
  • [42] Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
    Baldwin, David S.
    Schweizer, Edward
    Xu, Yikang
    Lyndon, Gavin
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 (02) : 137 - 142
  • [43] Association of symptom severity and adverse events with adherence to venlafaxine treatment in major depressive disorder
    Lee, C
    Chang, J
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S351 - S351
  • [44] Treatment of generalised anxiety disorder with venlafaxine XR - A randomised, double-blind trial in comparison with buspirone and placebo
    Rolland, PD
    Kablinger, AS
    Brannon, GE
    Freeman, AM
    [J]. CLINICAL DRUG INVESTIGATION, 2000, 19 (02) : 163 - 165
  • [45] Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder
    Kim, Tae-Suk
    Pae, Chi-Un
    Yoon, Su-Jung
    Bahk, Won-Myong
    Jun, Tae-Youn
    Rhee, Won-Ihl
    Chae, Jeong-Ho
    [J]. PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2006, 60 (03) : 347 - 351
  • [46] A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder
    Whalen, Paul J.
    Johnstone, Tom
    Somerville, Leah H.
    Nitschke, Jack B.
    Polis, Sara
    Alexander, Andrew L.
    Davidson, Richard J.
    Kalin, Ned H.
    [J]. BIOLOGICAL PSYCHIATRY, 2008, 63 (09) : 858 - 863
  • [47] Efficacy of venlafaxine XR and placebo in social anxiety disorder: Effects of gender and physical symptoms
    Liebowitz, M.
    Davidson, J.
    Blanco, C.
    Musgnung, J.
    Tummala, R.
    Jiang, Q.
    [J]. EUROPEAN PSYCHIATRY, 2007, 22 : S240 - S240
  • [48] Escitalopram vs. venlafaxine XR treatment of major depressive disorder
    Montgomery, S
    Bielski, RJ
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S169 - S169
  • [49] Generalized anxiety disorder: Nature and course
    Wittchen, HU
    Hoyer, J
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 : 15 - 21
  • [50] Mania after venlafaxine withdrawal in a patient with generalized anxiety disorder
    Khazaal, Yasser
    [J]. ANNALS OF PHARMACOTHERAPY, 2007, 41 (02) : 359 - 360